Background. The national human papillomavirus (HPV) immunization program was introduced in England in September 2008 using the bivalent vaccine.
the catch-up cohorts has been lower and more variable (ranging from 39% to 76%) [9] . A reduction in cervical cancer incidence is not expected for some years given the time interval between vaccination and the age of most cervical cancer diagnoses; thus, a reduction in the prevalence of HPV infection can provide an early indication of the effectiveness of the vaccination program. Data from several countries have already demonstrated reductions in vaccine types and HPV31, 33, and 45 since the introduction of national HPV vaccination programs [10, 11] .
In England, we utilize residual genital specimens, collected for chlamydia screening, for national HPV surveillance. We previously reported results showing lower prevalence of HPV16/18 following vaccination compared to before vaccination introduction, as well as some evidence of a reduction in HPV31 [12] [13] [14] . The latest of these reports [12] compared type-specific prevalence for 2354 specimens collected in 2008 to 7321 specimens collected from 2010 to 2013. These findings largely related to females eligible for catch-up vaccination. We now report an extension of these results with specimens collected to December 2016, including females eligible for routine vaccination.
We report trends in HPV16/18 prevalence since HPV vaccination began in England and vaccine-effectiveness estimates for the bivalent HPV vaccine. We compare findings to predictions from transmission dynamic model that informed the vaccination policy [15] . Evidence for herd-protection effects and for cross-protection against nonvaccine HPV types is also explored.
METHODS

Specimen and Data Collection
The methods for collection and testing of specimens and linkage with data have been described elsewhere [12, 14] . In brief, residual vulva-vaginal swab specimens were collected from 16 to 24-year-old women attending for chlamydia screening at general practices (GP), community and sexual health services (CaSH), or youth clinics. Residual specimens were collected from 10 laboratories where chlamydia testing was performed (Table 1) . Specimens were sent to the Virus Reference Department at Public Health England (PHE) for HPV testing. Demographic data were reported to PHE separately, either by the clinic (prior to 2012) or laboratory performing the chlamydia testing (from 2012). Demographic data were linked to specimens and, once linked, all other identifiable data were removed prior to HPV testing. Since 2015, samples were only requested from 16-20 year olds who would have largely been in routine vaccination cohorts. As these samples were Table 1 b Vaccination status data from Lewisham did not include the number of doses given as this was unavailable; these women were assumed to be fully vaccinated in our main analysis.
c Estimated using national HPV vaccination coverage for relevant birth cohorts.
collected for routine public health surveillance conducted to monitor the HPV vaccination program, individual patient consent was not required. PHE has permission to handle these data under section 251 of the UK National Health Service Act of 2006, which was renewed annually by the National Information Governance Board until 2013. Since then, the power of approval of public health surveillance activity has been granted directly to PHE. The present analysis included women who were eligible for bivalent HPV vaccination as part of the national program (born on or after 1 September 1990) as well as some too old to have been eligible. The latter were included to provide a comparison to vaccine-eligible women, and allow observation of changes in HPV prevalence due to herd protection. The number of women eligible for the quadrivalent vaccine in the national program (born on or after 1 September 1999) was very small; these women were excluded. Since 2014, HPV vaccination status has been retrospectively sought for specimens collected from women eligible for vaccination. Two different methods have been used to obtain these data: data obtained from laboratories from the chlamydia test request form, and data obtained by linkage with local Child Health Information Service (CHIS) Systems. The latter method could only be used if (1) chlamydia testing laboratories provided National Health Service (NHS) number, and (2) local CHIS system was able to conduct the linkage. One laboratory used the former method (Lewisham) and for 4 we used the latter method (Cambridge, Cornwall, Portsmouth, and Stoke). The completion of linkage to vaccine status varied greatly across these laboratories. For the remaining 5 laboratories, HPV vaccination status data were unavailable. Data collected from CHIS included the number of doses given and dates of each dose. Data collected from the chlamydia test request form was self-reported vaccination status and did not include information on the dates of doses. We assumed that vaccinated women with an unknown number of doses (126/1952; 6.5%) were fully vaccinated; this was explored further in sensitivity analyses.
Vaccination coverage for all women, stratified by year and age group, was estimated by combining individual-level vaccination coverage (those for whom vaccination status could be obtained) with the published national vaccination coverage (those for whom vaccination status could not be obtained).
HPV Testing
Eligible specimens were tested using an in-house multiplex polymerase chain reaction and Luminex-based genotyping test for 13 HR HPV types (HPV16/18/31/33/35/39/45/51/52/ 56/58/59/68), 5 possible HR types (HPV26/53/70/73/82), and 2 LR types (HPV6/11) [16] . An inadequate result was given if the samples were negative for both HPV and the housekeeping gene, pyruvate dehydrogenase [16] .
Statistical Analysis
We calculated the HPV prevalence and 95% confidence intervals (CI) for 3 age groups (16) (17) (18) (19) (20) (21) , and 22-24 year olds) and 4 time periods postvaccination (2010-2011, 2012-2013, 2014-2015, and 2016 [19] , and (6) additional HR HPV types included in the nonavalent HPV vaccine (HPV31/33/45/52/58). Changes in prevalence over time were compared using a log-binomial regression model, adjusted for age, testing venue, and chlamydia (as a marker for sexual behavior). For HPV16/18, previously published prevalence estimates for 2007/2008 (ie, prior to HPV vaccination) were included in trend analyses [13] . For all other HPV types, trend analysis considered changes within the postvaccination period only, due to differences in detection rates for certain types with the different assay used in the prevaccination period. This trend analysis approximated the effect of increasing vaccination coverage on HPV prevalence (ie, what are the changes in HPV prevalence as vaccination coverage increases over time). However, to further quantify the association between HPV vaccination coverage and changes in postvaccination HPV prevalence for all women across all years (2010-2016), we included a continuous variable in the regression model with the estimated HPV vaccination coverage (as a proportion). This allowed us to estimate an adjusted prevalence ratio for HPV infection comparing a population with no female vaccination (coverage = 0) with a fully vaccinated population (coverage = 1). Percentage declines in HPV16 and HPV18 within the postvaccination period were also plotted against predictions from a previously published model [15] . To do this, we input the published vaccination coverage [9] into this transmission dynamic model and calculated the percentage reductions for HPV16 and HPV18 from 100 best fitting scenarios to the prevaccination prevalence [15] . The median, minimum, and maximum of these 100 outputs were then calculated.
Prevalence ratios (PRs) comparing HPV prevalence in vaccinated versus unvaccinated women (for all years combined, 2010-2016) were calculated using a log-binomial regression model (adjusted [aPR] for age, testing venue type, and chlamydia positivity). Vaccine effectiveness was calculated as 1 − aPR. These analyses were stratified by age at vaccination (offered at 12-15 years old vs 16-17 years old).
In sensitivity analyses, we calculated vaccine effectiveness for women known to have had all vaccine doses in the recommended time interval. Specifically, we excluded women with (1) unknown number of doses (n = 126), and (2) vaccinated outside of the recommended dose schedule for the bivalent vaccine (n = 307). Table 1) .
The distribution of specimens by ethnicity has remained relatively stable with a slightly higher proportion of black women in 2010-2011 and an increasing proportion with missing ethnicity in more recent years. Over time, the proportion of samples from women attending GPs has increased, and the proportion from CaSH and youth clinics has decreased. Chlamydia positivity has decreased from just over 8% in 2010-2011 to around 6% in the later periods, likely reflecting changes in the population undergoing chlamydia screening. Changes in distributions of samples by ethnicity, recruitment venue, and chlamydia positivity were similar within each age group (data not shown).
As expected, the proportion of women who had been eligible for vaccination increased over time (Table 1) . This was partly due to a higher proportion of women in later years having been offered the vaccine at younger ages with higher national coverage but also due to a change in our sampling as we only requested samples from [16] [17] [18] [19] [20] Characteristics of women who would have been eligible for vaccination in the national program are given in Table 2 , stratified by vaccination status (unvaccinated, vaccinated, or unknown status). Among unvaccinated women, there was a slightly higher chlamydia positivity, a higher proportion of black women, and higher proportion of samples from family planning clinics compared to vaccinated women.
HPV16 and/or 18 Infection
In the younger age groups, HPV16/18 prevalence decreased within the postvaccination period between 2010/2011 to 2016 from 8.2% to 1.6% in 16-18 year olds and 14.0% to 1.6% in 19-21 year olds (compared to 17.6% and 16.9% in the prevaccination period [13] , respectively; P trend for both age groups < .001; Table 3, Figure 1 ). These decreases were strongly associated with the increasing estimated vaccination coverage (aPR 0.2; 95% CI, 0.1-0.3 and aPR 0.3; 95% CI, 0.2-0.4 for 16-18 and 19-21 year olds, respectively). In the oldest age group, the prevalence in 2014-2015 was 7.5% compared to 16.4% in 2010-2011 (15.3% in the prevaccination period [13] ; P trend .417) although when we considered changes relative to vaccination coverage, there was evidence of an association (aPR 0.3; 95% CI, 0.1-0.6) ( Table 3 ). Observed percentage reductions were similar to model predictions for both HPV types ( Figure 2 ).
The prevalence of HPV16/18 in cohorts offered routine vaccination was 2.0% (95% CI, 1.5%-2.4%) and 1.3% (95% CI, 0.7%-2.0%) in those aged 16-18 years and 19-21 years at sample collection respectively.
Among the subset of women with known vaccination status, full-course vaccine effectiveness against HPV16/18 was 82.0% (95% CI, 60.6%-91.8%) for women vaccinated <15 years and 48.7% (95% CI, 20.8%-66.8%) for women vaccinated at 15-17 years (Table 4, Figure 3 ).
HPV31, 33 and/or 45 Infection
In the younger age groups, there was evidence of a decrease in the prevalence of HPV31/33/45 within the postvaccination Figure 3 ).
Nonvaccine HR HPV Types
In 16-18 year olds, the prevalence of non-16/18/31/33/45 HPV types remained relatively stable at 31.0% in 2010-2011 to 26.7% in 2016 (P trend .211). The prevalence also remained relatively stable for 19-21 year olds (34.0% in 2010-2011 to 32.9% in 2016; P = .877) but there was a slight increase among 22-24 year olds (27.0% in 2010-2011 to 31.7% in 2014; P < .001).
The prevalence of HPV6/11 remained relatively constant over time (Table 2 ). Among those with HPV vaccination status, there was no protective effect of the bivalent vaccine against these HPV types (vaccine effectiveness 26.5%; 95% CI, −26.8% to 57.4% for women vaccinated <15 years and 18.8%; 95% CI, −24.6% to 47.1% for women vaccinated at 15-17 years).
Sensitivity Analysis
Restricting vaccine-effectiveness estimates to women who were known to have 3 HPV vaccine doses within the recommended schedule gave very similar results to the main analysis for HPV16/18 (vaccine effectiveness 81.7%; 95% CI, 58.8%-91.8% for vaccination <15 years and 47.9%; 95% CI, 17.7%-67.1% for vaccination at age [15] [16] [17] . 
DISCUSSION
We have previously reported changes in the prevalence of HPV types between the pre-and postvaccination period [12, 14] . Interpretation of these findings was complicated by a change in the HPV assay used between the pre-and postvaccination periods. In this report, we consider changes over time within the postvaccination period during which testing was conducted consistently with our in-house assay. If HPV vaccination is causing a change in certain HPV types we expect to see these changes strengthening over time since vaccination, as later periods include women vaccinated at a younger age and with higher vaccination coverage. Additionally, for a subset of women with vaccination status, we have calculated vaccine effectiveness.
Among ages offered HPV vaccination, we have demonstrated clear reductions in infections with the HPV vaccine types since the introduction of the HPV vaccination program in England, with greater reductions in younger women (with higher vaccination coverage and vaccinated at a younger age).Vaccine effectiveness in those vaccinated <15 years was high, as expected given the high vaccine efficacy from per-protocol analyses of clinical trials [2, 3, 6, 7] . The lower effectiveness in the older catch-up females is also to be expected, given risk of prior exposure to HPV. We have compared percentage declines in HPV vaccine types in this surveillance with predicted outputs from a dynamic transmission model conducted prior to the introduction of HPV vaccination in England [15] . These results provide reassurance that observed declines in HPV16/18 prevalence are similar to what was expected.
Encouragingly, there is also evidence of a substantial herd protection effect with HPV16/18 prevalence also reducing over b P values for trend compare changes in prevalence over time using a log-binomial regression model, adjusted for age, testing venue, and chlamydia positivity.
c Prevalence ratios for the association between estimated HPV vaccination coverage and changes in postvaccination HPV prevalence.
d Adjusted for age, venue type, and chlamydia positivity. Table 3 . Continued time in unvaccinated women, which is consistent with data from other countries [10, 20, 21] . We have also seen clear evidence of cross-protection following introduction of a bivalent vaccine with declines in HPV31/33/45 within the postvaccination period overall. In the younger age groups, percentage reductions over time have been similar for vaccine types and HPV31/33/45 (Figure 1 ) despite lower vaccine effectiveness for HPV31/33/45. This is consistent with predictions from mathematical modeling; that the lower basic reproductive number for some HPV types means herd protective effects could be greater [22] (ie, it may be easier to reduce prevalence of types with a lower basic reproductive number, such as HPV18, HPV31, HPV33, and HPV45, as herd protection effects are stronger).
We have previously reported increases in nonvaccine types between the pre-and postvaccination periods and potential reasons for this were discussed [12] . In this analysis we have seen stable prevalence of non-16/18/31/33/45 HR types within the postvaccination period. This is not consistent with what we would expect to see if vaccination against HPV16/18 was driving increases of other nonvaccine types, or type replacement. This supports our caution in prior discussion of the changes between the prevaccination and postvaccination periods to end 2014, and suggests these were likely unrelated to HPV vaccination.
Our results for reductions in the HPV vaccine types are consistent with elsewhere in the UK and worldwide. A systematic review and meta-analysis demonstrated decreases in HPV16/18 prevalence among 13-19 year old women (risk ratio 0.32; 95% CI, 0.19-0.52) [10] . A large study of over 12 000 samples from 13 to 22-year-old women attending for chlamydia screening in Sweden showed a reduction in HPV16 (from 14.9% prevaccination to 8.7% postvaccination) and HPV18 (7.9% to 4.3%) [23] . Another study of 1087 16 to 22-year-old women, which was conducted in The Netherlands, compared HPV prevalence in vaccinated versus unvaccinated women and demonstrated a slightly higher vaccine effectiveness against HPV16/18 of 89.9% (95% CI, 81.7%-94.4%) [24] . Updated data from Scotland have reported similar results with a vaccine effectiveness against HPV16/18 of 89% (95% CI, 85%-92%) among those vaccinated at age 12-13 years [20] . However, evidence for changes in the nonvaccine types is less consistent across different studies. The meta-analysis conducted by Drolet et al demonstrated a reduction in HPV31/33/45 combined (risk ratio 0.72; 95% CI, 0.54-0.96) for both vaccines combined. However, a related systematic review and meta-analysis, which considered changes in individual nonvaccine types only, demonstrated reductions in HPV31 in women ≤19 years old but not HPV33 or HPV45 [11] . In a study in Sweden, where the quadrivalent vaccine has been used, there was also some suggestion of a reduction in HPV31 but not in the other closely related HPV types [23] . However, a more recent study of 8584 20 to 21-year-old women attending for cervical screening in Scotland, where the bivalent vaccine was used, demonstrated a lower prevalence among vaccinated women compared to unvaccinated women for types HPV31/33/45 individually and a very high combined vaccine effectiveness of 85.1% and 83.6% in women vaccinated at 12-13 years and 14 years, respectively [20] . Similarly, data from The Netherlands, where the bivalent vaccine was adopted, has also shown lower prevalence of HPV31/33/45 among vaccinated compared to unvaccinated women [24] . There are certain limitations of our surveillance that should be taken into account when interpreting these results. Firstly, analyses comparing changes in HPV prevalence over time may reflect changes due to HPV vaccination; however, other changes at a population level, or individual differences not adjusted for in our analysis, should not be ruled out. We have adjusted for the testing venue, age, and chlamydia positivity, but the extent to which changes in sexual behavior (in addition to the adjustment for chlamydia positivity) or other unrecorded changes have affected HPV prevalence estimates is unclear. Secondly, there may be inequalities in HPV vaccination uptake that affect our analyses of vaccine effectiveness and estimation of herd protection effects. We have compared characteristics by vaccination status (Table 2 ) and, similarly to the above, we have attempted to address these inequalities by adjusting for venue type, age, and chlamydia positivity. However, there may be other factors associated with vaccine uptake and HPV prevalence that have not been accounted for. Calculation of vaccine effectiveness was only possible for women with known vaccination status (21% of women eligible to receive the vaccine). The women with vaccination data available may not be representative of all women included in this study as missing vaccination status occurred largely at an area level (either laboratories not providing NHS number or local CHIS systems not being able to conduct linkage). Over 80% of these specimens came from one testing laboratory in Cornwall. Vaccination in Cornwall differed from the vast majority of other areas in England as the vaccine was largely delivered during these years in primary care (rather than schools). As such, if there is any reason that this method of vaccine delivery could affect vaccine effectiveness then these results may not be representative of the rest of England. For example, vaccination at primary care is likely to lead to vaccine doses given outside of the optimum schedule as individuals will need to be followed up individually for second and third doses, which is likely to underestimate vaccine effectiveness. However, excluding women who received 3 doses of the vaccine outside of the recommended schedule had little effect on the vaccine effectiveness (from 82.0% to 81.7% for 16-18 year olds). A further limitation of our analysis of vaccine effectiveness is the relatively small number of unvaccinated women, particularly at younger ages. Consequently, some confidence intervals for vaccine effectiveness are wide.
This large surveillance includes HPV results from over 15 000 samples, which have allowed us to consider a breadth of analyses to monitor changes in the prevalence of HPV infection in young women since the introduction of national HPV vaccination. A key strength of this analysis is the ability to monitor the population effects of vaccination prior to these women entering cervical screening, therefore offering information to inform screening services. We demonstrate dramatic declines in the prevalence of vaccine HPV types in this population, similar to predictions from effectiveness models. We also demonstrate clear evidence of declining prevalence of HPV31/33/45, most likely attributable to cross-protection. As cervical screening is changing to HPV testing as a primary screen our data can inform decisions regarding HPV testing strategies. These data should also be used to inform assessments of the additional benefit of introducing the nonavalent vaccine to the national vaccination program. 
